Date: 2017-03-18
Type of information: Private placement
Company: Audentes Therapeutics (USA - CA)
Investors:
Amount: $75.4 million
Funding type: private placement
Planned used:
Others:
- • On April 18, 2017, Audentes Therapeutics announced the pricing of its underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $14.50 per share before underwriting discounts and commission. The gross proceeds to Audentes from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Audentes, are expected to be approximately $75.4 million. In addition, Audentes has granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of common stock. The offering is expected to close on April 24, 2017, subject to customary closing conditions. BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as a co-manager.
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
